Story type: Industry
-
New CRC-P Grant accelerates Microbiome therapeutics
Hudson Institute partner BiomeBank has secured a multimillion-dollar Federal Government grant that will turbocharge the development and production of microbiome-based therapeutics.… Read more
-
New anti-inflammatory drug – one medicine to rule them all
A new class of anti-inflammatory drug is opening a world of possibilities for treating everything from neurological diseases to cancers.… Read more
-
CUREator funds Hudson Institute biotech innovation
Exciting new treatments for unmet medical needs including ovarian cancer have been awarded significant funding from Australia’s national biotechnology incubator, CUREator.… Read more
-
Passing the baton
Congratulations to Professor Ron Firestein, who was announced this week as Deputy Director of Hudson Institute of Medical Research.… Read more
-
Professor Elizabeth Hartland to Chair VicAAMRI
The CEO of Hudson Institute of Medical Research, Professor Elizabeth Hartland, has been appointed chair of the Victorian chapter of AAMRI, the Association of Australian Medical Research Institutes.… Read more
-
Targeting viral lung infections two ways
A new anti-viral drug to target the cause of viral lung infections and the infection itself could be a game-changer in treating severe influenza.… Read more
-
Making more effective and efficient RNA therapeutics
RNA technology developed by Hudson Institute of Medical Research with the potential to limit inflammatory side-effects of RNA therapeutics such as mRNA vaccines, is the subject of a new licensing deal.… Read more
-
World-leading National Centre for Inflammation Research to be established in Victoria following budget boost
Hudson Institute of Medical Research today welcomed the Victorian Government’s initial investment to kick-start a National Centre for Inflammation Research (NCIR) to be established at the Monash Health Translation Precinct (MHTP) in Melbourne’s growing south-eastern corridor.… Read more
-
Medical research to benefit from Morningside Ventures appointment
Australia’s medical research sector will benefit from the appointment of Hudson Institute inflammation scientist Associate Professor Ashley Mansell to global firm Morningside BioPharma Advisory,… Read more
-
Future leaders selected for industry mentoring
Ten Hudson Institute PhD students have been selected for the first time to participate in the high-level mentoring program, Industry Mentoring Network in STEM (IMNIS).… Read more